Evidence, Insight and Strategy for Optimizing Health Benefits

Tuesday, May 8 - Thursday, May 10, 2018
Harvard Medical School, Boston, MA

Registration coming soon!

harvard medical school: executive education
Conference begins in:


Jeff Levin-Scherz, M.D., M.B.A., F.A.C.P.

Assistant Professor
Harvard Medical School
Harvard T.H. Chan School of Public Health

Jeff Levin-Scherz is an assistant professor at Harvard Medical School and the Harvard T.H. Chan School of Public Health and a senior consultant and the co-leader of North American Health Management Practice at Willis Towers Watson. He helps large employers develop, implement and evaluate their health management strategy, including care management programs, incentive programs, and technology programs. Jeff leads intellectual capital development for Willis Towers Watson in the Health Management space.

Jeff has written and spoken widely on health care delivery and reform, especially around the adoption of disruptive innovation, and the use of behavioral economics to drive performance in the health care delivery system and behavior among employees and in the general population.  His work has been published in JAMA, the Journal of General Internal Medicine, and the Harvard Business Review. He is a co-author of "Human Centric Health: Behavior Change and Prevention of Non-Communicable Diseases" presented at the World Economic Forum in Davos, Switzerland, in January, 2017

Jeff has a broad range of experience in health care delivery and finance. He was the President of a regional independent practice association, Chief Medical Officer of the network division of Partners HealthCare and of Atrius Health, a multispecialty group with 1000 physicians, as well as One Medical, a venture funded national high tech high touch primary care practice. Jeff also served for seven years as a vice president of Tufts Health Plan, a top-ranked regional health plan. Jeff holds an M.D. from the Boston University School of Medicine, and received his M.B.A. from Columbia Business School.


Zirui Song, M.D., Ph.D.

Assistant Professor
Harvard Medical School
Internal Medicine Physician
Massachusetts General Hospital

Zirui Song, M.D., Ph.D. is an assistant professor of health care policy at Harvard Medical School and a primary care physician at Massachusetts General Hospital. Dr. Song's research focuses on the impact of payment reform on health care spending and quality, the impact of Medicare fee policies on spending and physician behavior, and the economics of private plans in Medicare. This work has been published in the New England Journal of Medicine, JAMA, Health Affairs, and Journal of Health Economics.

Dr. Song is a recipient of the AcademyHealth Article-of-the-Year award, Award for Clinician Investigation from the New England Society of General Internal Medicine, and the Emerging Leader in Managed Care Research Award from the American Journal of Managed Care. He has received three Certificates of Distinction in teaching from Harvard College and two teaching awards at Harvard Medical School. He has worked on policy issues in the Department of Health and Human Services in Washington, D.C., served as a visiting fellow in the Health Policy Commission for the state of Massachusetts, and was a special guest in the Center for Social and Economic Dynamics at the Brookings Institution.

Dr. Song completed his residency training at Massachusetts General Hospital, where he was selected by peers for the Morton N. Swartz, M.D. Humanism in Medicine Award. He received his M.D. from Harvard Medical School, magna cum laude, and Ph.D. in Health Policy (Economics track) from Harvard University, where he was a fellow in Aging and Health Economics at the National Bureau of Economic Research.


Meredith Rosenthal, Ph.D.

Senior Associate Dean for Academic Affairs, Professor of Health Economics and Policy
Harvard Medical School
Harvard T.H. Chan School of Public Health

Dr. Rosenthal is Senior Associate Dean for Academic Affairs,
Professor of Health Economics and Policy, Harvard TH Chan School of Public Health. She received her B.A in International Relations (Commerce) from Brown University in 1990 and her Ph.D. in Health Policy (Economics track) from Harvard University in 1998.

Her research focuses primarily on policies that will help slow the growth in healthcare spending and improve value. These efforts include changes in payment incentives, benefit design, and the provision of information and behavioral "nudges" to both patients and providers. Her research has influenced the design of provider payment systems in both the public and private sectors. She has advised federal and state policymakers in healthcare payment policy and implementation. She has also testified in Congressional hearings on direct-to-consumer advertising of prescription drugs and pay-for-performance and in legislative hearings in California and Massachusetts concerning healthcare provider payment and benefit design policies.

Dr. Rosenthal is a member of the Committee on Higher Degrees in Health Policy, the Massachusetts Center for Healthcare Information and Analysis Oversight Board, and Board Chair of Massachusetts Health Quality Partners, a multi-stakeholder quality improvement organization. Dr. Rosenthal's work has been published in the New England Journal of Medicine, the Journal of the American Medical Association, Health Affairs, and numerous other peer-reviewed journals. In 2014, Dr. Rosenthal was elected to the Institute of Medicine (recently renamed the National Academy of Medicine).


Sree Chagaturu, M.D.

Vice President, Population Health Management
Partners HealthCare

Sree Chaguturu is Vice President of Population Health Management at Partners HealthCare. Partners is an integrated health care delivery system in Boston, Massachusetts, that includes two large academic medical centers—Massachusetts General Hospital and Brigham and Women's Hospital— with more than 6000 physicians. Dr. Chaguturu is part of the leadership team focused on insuring that Partners meets its aspirations of improving quality and reducing costs for the populations they serve. His responsibilities broadly are related to health care delivery innovation and include coordinating Partners' efforts implementing the Medicare Pioneer Accountable Care Organization as its Chief Medical Officer and assisting with the development of information technology solutions necessary to support population health programs. Prior to joining Partners, Dr. Chaguturu was a health care consultant at McKinsey and Company. Rising to Vice President of the McKinsey Hospital Institute, he developed extensive experience advising chief executive teams and government leaders on provider post-reform strategy, including health care delivery innovation, population health management, quality improvement and clinical variability reduction. He is a practicing internal medicine physician at Massachusetts General Hospital and a clinical instructor at Harvard Medical School. Dr. Chaguturu received his internal medicine and primary care training at Massachusetts General Hospital and received his undergraduate and medical degree from Brown University.



Dana Gelb Safran, Sc.D.

Senior Vice President of Performance Measurement and Improvement
Blue Cross Blue Shield of Massachusetts (BCBSMA)

Dr. Dana Gelb Safran serves as Senior Vice President of Performance Measurement and Improvement at Blue Cross Blue Shield of Massachusetts (BCBSMA). In this role, Dr. Safran leads its initiatives to measure and improve healthcare quality, safety and outcomes. Dr. Safran also retains an active academic practice and is Associate Professor of Medicine at Tufts University School of Medicine. She serves as Co-Chair of Center for Accountable Care at Patient Centered Primary Care Collaborative. She serves as a Director of Partnership for Healthcare Excellence Inc. and Massachusetts Health Quality Partners Inc.

Prior to joining BCBSMA, she was Director of The Health Institute at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies. Dr. Safran is widely recognized as having contributed to the empirical basis for nation's push toward a more patient-centered health care system – and for developing measures of patient care experiences that are used nationwide, accepted as a national standard for this area of measurement and used by the Medical Boards as part of their recertification process for physicians.

Dr. Safran is an active member of multiple healthcare quality boards and committees locally and nationally including her role as a technical advisor to the National Quality Forum (NQF), a Governor's appointee to the Advisory Committee of the Massachusetts Healthcare Quality and Cost Council, Clerk and Board Member of the Partnership for Health Care Excellence (PHCE). Dr. Safran holds Doctor of Science degree in Health Policy from Harvard School of Public Health.


Aaron Kesselheim M.D., J.D., M.P.H.

Associate Professor of Medicine
Harvard Medical School
Faculty Member, Division of Pharmacoepidemiology and Pharmacoenomics
Department of Medicine
Brigham and Women's Hospital

Aaron S. Kesselheim, M.D., J.D., M.P.H., is an Associate Professor of Medicine at Harvard Medical School and a faculty member in the Division of Pharmacoepidemiology and Pharmacoeconomics in the Department of Medicine at Brigham and Women's Hospital. He graduated from Harvard College and received his postgraduate training at the University of Pennsylvania School of Medicine and Law School, and most recently at the Harvard School of Public Health. He is Board Certified in Internal Medicine, and serves as a primary care physician at the Phyllis Jen Center for Primary Care at BWH. His research focuses on the effects of intellectual property laws and regulatory policies on pharmaceutical development, the drug approval process, and the costs, availability, and use of prescription drugs both domestically and in resource-poor settings. He has also investigated how other issues at the intersection of law and public health can affect the health care system, including health care fraud, expert testimony in malpractice cases, and insurance reimbursement practices. He is a member of the New York State Bar and is a Patent Attorney.

Within the Division, Dr. Kesselheim leads the Program On Regulation, Therapeutics, And Law (PORTAL), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. In 2013, Dr. Kesselheim was named a Greenwall Faculty Scholar in Bioethics by the Greenwall Foundation, which supports innovative empirical research in bioethics. Dr. Kesselheim's work is also currently funded by the FDA, Laura and John Arnold Foundation, and by a Robert Wood Johnson Investigator Award in Health Policy Research. In the past, he has received research support from the Edmond J. Safra Center for Ethics at Harvard University, AHRQ, Pew Charitable Trusts, and the Harvard Clinical and Translational Science Center.


Ateev Mehrotra, M.D., M.P.H.

Associate Professor of Health Care Policy and Medicine
Harvard Medical School
Hospitalist
Beth Israel Deaconess Medical Center

Ateev Mehrotra, is an associate professor of health care policy and medicine at Harvard Medical School and a hospitalist at Beth Israel Deaconess Medical Center. Dr. Mehrotra's research focuses on interventions to decrease costs and improve quality of care. Much of his work has focused on innovations in delivery such as retail clinics and telemedicine and their impact on quality, costs, and access to health care. He is also interested in the role of consumerism and whether price transparency and public reporting of quality can impact patient decision making. Related work has focused on quality measurement, including how natural language processing can be used to analyze the data in electronic health records to measure the quality of care. Dr. Mehrotra received his BS from the Massachusetts Institute of Technology, his medical degree from the University of California, San Francisco and his residency in internal medicine and pediatrics at the Massachusetts General Hospital and Children's Hospital of Boston. His clinical work has been both as a primary care physician and as an adult and pediatric hospitalist. He also has received formal research training with a Master of Public Health from the University of California, Berkeley and a Master of Science in Epidemiology from the Harvard School of Public Health. In 2013, he received the Alice S. Hersh New Investigator Award from AcademyHealth for health services researchers early in their careers who show exceptional promise



Niteesh K. Choudhry, M.D., Ph.D.

Professor of Medicine at Harvard Medical School
Executive Director of the Center of Healthcare and Delivery Sciences
Associate Physician, Division of Pharmacoepidemiology and Pharmacoconomics
Brigham and Women's Hospital

Niteesh K. Choudhry is an internist and health services researcher whose work focuses on the development and evaluation of novel strategies to improve health care quality and reduce spending.  He is Professor of Medicine at Harvard Medical School, the founding Executive Director of the Center for Healthcare Delivery Sciences and an Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics, at Brigham and Women's Hospital, where he is also a practicing hospitalist.  He is also Professor in the Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health and Director of Implementation Research and Education at Harvard Catalyst.

Much of Dr. Choudhry's current research deals with non-adherence to evidence-based medications, a problem that is estimated to cost almost $300 billion annually in the U.S. alone. He has led and is leading numerous clinical trials embedded in real-world health systems aimed at addressing this issue.  He was the principal investigator of the Post-MI Free Rx and Event and Economic Evaluation (MI FREEE) trial, on the basis of which Aetna has changed their benefits to waive medication copayments for post-MI secondary prevention medications.  He is the principal investigator of the National Heart Lung and Blood Institute-funded Study of a Telepharmacy Intervention for Chronic disease to Improve Treatment adherence (STIC 2 IT), the Robust Evaluation to Measure Improvements in Nonadherence from low-cost Devices (REMIND) trial, supported by CVS Health, the Targeted Adherence intervention to Reach Glycemic control with Insulin Therapy for Diabetes patients (TARGIT - Diabetes) study, funded by Sanofi, and the ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) trial, funded by Astra Zeneca. In collaboration with the U.S. Behavioral Insights Team, the Center for Medicare and Medicaid Services and the National Vaccines Program Office, he is also Co-Principal Investigator of the Mail Outreach To Increase Vaccination Acceptance Through Engagement (MOTIVATE) trial.


Nancy L. Keating, M.D., M.P.H.

Professor, Health Care Policy and Medicine
Harvard Medical School
Physician
Brigham and Women's Hospital

Nancy L. Keating is a professor of health care policy and medicine at Harvard Medical School and a physician at Brigham and Women's Hospital. Dr. Keating's research examines provider, patient, and health system factors that influence the delivery of high-quality care for individuals with cancer. 

Dr. Keating is currently evaluating the Center for Medicare and Medicaid Service's Oncology Care Model, a new payment and delivery model for oncology practices administering chemotherapy. This model aims to use appropriately aligned financial incentives to improve care coordination, appropriateness of care, and access to care for Medicare beneficiaries undergoing chemotherapy at approximately 250 practices in the U.S., and the evaluation will assess patients' experiences with care, quality of care, health care utilization, and outcomes. 

Dr. Keating is a longstanding member of the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium, funded by the National Cancer Institute (NCI). This is a collaborative effort among investigators at seven sites to examine patterns of care and outcomes for patients with colorectal and lung cancer. Using CanCORS data linked with Medicare administrative data, she is seeking to better understand patient, physician, and health system factors contributing to the variations in the intensity of end-of-life (EOL) care for individuals with advanced cancer. In other work funded by the NCI, she is examining the influence of physician networks on care to understand the diffusion of cancer care practices over time, focusing on the use of new biologic therapies for cancer and care at the end of life. 

In another project funded by the NCI, Dr. Keating is using data from the Massachusetts Cancer Registry linked with the Massachusetts All-Payer Claims Database to examine variations in the quality and costs of cancer care across provider networks in Massachusetts. Dr. Keating also has a K24 grant from the NCI that is applying from behavioral economics techniques to improve discussions and understanding of goals of chemotherapy for individuals with advanced cancer. Finally, with funding from the American Cancer Society, she is examining the impact of oral cancer drug parity laws, which have been adopted in 23 states since 2007, to ensure that patients pay no more for oral anti-cancer therapies than they pay for intravenous therapies offered by the same health plan. Findings from this study will inform current efforts in Congress to pass similar national legislation. 

Dr. Keating received her MD from the University of Chicago Pritzker School of Medicine and her MPH from the Harvard School of Public Health. She was awarded the Outstanding Junior Investigator Award from the Society of General Internal Medicine in 2005. She is an associate editor at the Journal of the National Cancer Institute, a member of the editorial board of the Journal of Geriatric Oncology, and a member of the National Comprehensive Cancer Center Senior Oncology Guideline Panel. She recently completed 3-year terms on the Council of the Society of General Internal Medicine and the American Society of Clinical Oncology Clinical Practice Guidelines Committee. Dr. Keating recently served on the Institute of Medicine Committee: Clinical Guidance for the Care of Health Conditions Identified by the Camp Lejeune Legislation.


Daniel Stein, M.D.

CEO and Founder
Better Medicine
Clinical and Strategy Advisor
Walmart 


Daniel Stein is the CEO and Founder of Better Medicine, a provider analytics and network optimization company. He also serves as a clinical and strategy advisor for Walmart. Daniel previously worked as Chief Medical Officer for Walmart Care Clinics, where he co-founded and led Walmart's primary care clinic business, Walmart Care Clinics, as well as other healthcare initiatives. Previously, Daniel worked on the health staff of the U.S. Senate Finance Committee on policy involving Medicare and Medicaid. In this capacity, Daniel worked extensively on the Medicare Modernization Act of 2003, the Medicare prescription drug legislation, and medical malpractice reform. Daniel returned the U.S. Senate Finance Committee in 2009 to help formulate health care workforce and delivery system reform proposals for Senator Baucus' comprehensive health reform buill which formed the foundation for the Accountable Care Act. Daniel also worked previously at the Centers for Medicare and Medicaid Services (CMS) where his work focused on Medicare quality and pay-for-performance initiatives.

In addition, Daniel also practices part-time as primary care physician at the Veterans Health Care Systems of the Ozarks in Fayetteville, Arkansas. 

Daniel received his undergraduate degree in Ethics, Politics, and Economics from Yale College; his medical degree from the Johns Hopkins School of Medicine; and his MBA from the Harvard Business School. He completed his residency in primary care internal medicine at Brigham and Women's Hospital where he was honored with the John H. McArthur Fellowship in Medicine and Management.


Stanley Y. Shaw, M.D., Ph.D.

Associate Dean for Executive Education
Harvard Medical School
Board - Certified Cardiologist

Stanley Y. Shaw, M.D., Ph.D.  is the Associate Dean for Executive Education at Harvard Medical School. In this role, he designs and leads customized, experiential executive programs for companies and individuals from diverse sectors of health care, including technology, health IT, internet search, biopharmaceuticals, and investing. He is the Chief Scientific Officer for One Brave Idea (at Brigham and Women's Hospital), a $75M initiative funded by the American Heart Association, Verify (formerly Google Life Sciences) and Astra Zeneca to understand and treat the underlying causes of coronary heart disease. He leads reserach efforts in digial health, bioinformatics, the gut microbiome and non-traditional streams of patient-reported data. Previously, Dr. Shaw co-founded the Center for Assessment Technology and Continious Health (CATCH) at Massachusetts General Hospital (MGH), and his team led the development of one of the first ResearchKit iPhone apps (for type 2 diabetes) in partnership with Apple. He is a board-certified cardiologist. 



Ronald C. Kessler, Ph.D.

McNeil Family Professor of Health Care Policy
Harvard Medical School

Dr. Kessler's research deals broadly with the social determinants of mental health and illness as studied from an epidemiological perspective. He is the author of over 700 publications and the recipient of many awards for his research, including the Senior Scientist and MERIT awards from the National Institute of Mental Health. He has been rated as the most widely cited researcher in the world in the field of psychiatry for each of the past fifteen years and is a member of both the Institute of Medicine and National Academy of Sciences.

Dr. Kessler is the Principal Investigator of the US National Comorbidity Survey, the first nationally representative survey of the prevalence and correlates of mental disorders in the U.S., and a Co-Director of the World Health Organization's World Mental Health Survey Initiative, a series of comparative community epidemiological surveys of the prevalence and correlates of mental disorders and treatment for these disorders in 26 countries around the world. In addition, to his epidemiological studies, Dessler is involved in evaluating a number of innovative programs for the prevention and treatment of mental illness in high-risk segments of the population. Dr. Kessler is the Principal Investigator of the Harvard Medical School sites for STARRS-LS, a research program funded by the Department of Defense to study risk and protective factors for suicide among Army personnel, and the AURORA study, a prospective study of the temporal unfolding of adverse neuropsychiatric reactions to traumatic life events among patients presenting to emergency departments in the wake of such events. 

Dr. Kessler earned his Ph.D. in sociology from New York University in 1975. He completed a postdoctoral fellowship in psychiatric epidemiology at the University of Wisconsin before joining the faculty at the University of Michigan in 1979. He was a professor of Sociology and Program Director at Michigan's Institute for Social Research at the time he tool his current position at Harvard Medical School in 1994.


Suzanne F. Delbanco

Executive Director
Catalyst for Payment Reform

Ms. Delbanco is the executive director of Catalyst for Payment Reform (CPR). CPR is an independent, nonprofit corporation working to catalyze employers, pubic purchasers and others to implement strategies that produce higher value health care and improve the functioning of the health care marketplace. In addition to her duties at CPR, she serves on the advisory board of the Blue Cross Blue Shield Institute and participates in the health care executives' leadership network. Previously, Ms. Delbanco was the founding cheif executive officer of The Leapfrog Group. She holds a Ph.D. degree in public policy from the Goldman School of Public Policy and an M.P.H. degree from the school of public health at the University of California, Berkeley.